多参数磁共振/超声融合引导活检减少非洲裔美国男性惰性前列腺癌的检出
这项前瞻性队列研究纳入2007至2015年疑似前列腺癌的非洲裔美国男性,比较融合引导活检(FBx)与系统12针活检(SBx)及其联合方案。FBx联合SBx较单用SBx检出更多临床显著前列腺癌(80例 vs 62例,P=0.004),且未显著增加临床不显著前列腺癌的检出。
要点
- FBx与SBx在非洲裔美国男性中风险分类完全一致的比例为64%。
- FBx较SBx检出临床不显著前列腺癌减少41%(FBx 30例 vs SBx 51例,P=0.0004)。
- FBx联合SBx较单用SBx检出更多临床显著前列腺癌(80例 vs 62例,P=0.004)。
核心结论
- FBx与SBx联合应用于非洲裔美国男性时检出更多临床显著前列腺癌,同时未显著增加临床不显著前列腺癌的诊断。
- 作者指出未来需要多中心研究来最终验证FBx在非洲裔美国患者中的临床意义。
研究设计与样本
- 机构审查委员会批准的前瞻性队列研究,纳入2007至2015年疑似前列腺癌的男性,均接受mpMRI及FBx并同期行SBx。
- 收集患者人口学、影像学和融合活检变量,采用χ2检验、Mann-Whitney U检验和McNemar检验分别比较比例、均值和配对变量。
- 临床显著前列腺癌(CSPCa)定义为Gleason评分⩾3+4。
主要发现
- FBx与SBx风险分类完全一致的比例为64%。
- FBx与SBx检出CSPCa无统计学显著差异(FBx 68例 vs SBx 62例,P=0.36)。
- FBx较SBx检出临床不显著前列腺癌(CIPCa)减少41%(FBx 30例 vs SBx 51例,P=0.0004)。
- FBx联合SBx较单用SBx检出更多CSPCa(FBx/SBx 80例 vs SBx 62例,P=0.004),CIPCa检出数相当(FBx/SBx 45例 vs SBx 51例,P=0.37)。
- 在有既往SBx阴性史的患者中,FBx联合SBx较单用SBx检出更多CSPCa(FBx/SBx 28例 vs 19例,P=0.003)。
关键数值与推荐
- 临床显著前列腺癌(CSPCa)定义为Gleason评分⩾3+4。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出未来需要多中心研究来最终验证FBx在非洲裔美国患者中的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Analysis of systematic 12-core biopsies (SBx) has shown that African-American (AA) men tend to harbor higher risk prostate cancer (PCa) at presentation relative to other races. Multiparametric magnetic resonance imaging (mpMRI) and MRI-ultrasound fusion-guided biopsy (FBx) have been shown to diagnose more intermediate- and high-risk PCa in the general population; however, the efficacy in AA remains largely uncharacterized. We aim to evaluate the utility of FBx in an AA patient cohort. METHODS: Men suspected of PCa underwent an mpMRI and FBx with concurrent SBx from 2007 to 2015 in this institutional review board-approved prospective cohort study. Patient demographics, imaging and fusion biopsy variables were collected. χ2, Mann-Whitney U-test and McNemar's tests were performed to compare proportions, means and paired variables, respectively. Clinically significant PCa (CSPCa) was defined as Gleason score ⩾3+4. RESULTS: Fusion biopsy demonstrated exact agreement with SBx risk categories in 64% of AA men. There was no statistically significant difference in the detection of CSPCa between FBx vs SBx (68 vs 62 cases, P=0.36). However, FBx detected 41% fewer cases of clinically insignificant PCa (CIPCa) compared with SBx (FBx 30 vs SBx 51 cases, P=0.0004). The combined FBx/SBx biopsy approach detected significantly more cases of CSPCa (FBx/SBx 80 vs SBx 62 cases, P=0.004) while detecting comparable number of cases of CIPCa (FBx/SBx 45 vs SBx 51 cases, P=0.37) compared with SBx alone. FBx/SBx also detected more CSPCa in patients with a history of prior negative SBx (FBx/SBx 28 vs 19 cases, P=0.003). CONCLUSIONS: FBx when used in combination with SBx detected more cases of CSPCa while not significantly increasing the diagnosis of CIPCa in AA men. Future multicenter studies will be needed to validate ultimately the clinical implications of FBx in AA patients.
引用
- Kongnyuy M, Siddiqui MM, George AK, et al. Multiparametric MRI/ultrasound fusion-guided biopsy decreases detection of indolent cancer in African-American men. Prostate Cancer Prostatic Dis. 2017. PMID: 28440325. doi:10.1038/pcan.2017.21
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。